Pierre Feugier

TL;DR: 2 years of rituximab maintenance therapy after immunochemotherapy as first-line treatment for follicular lymphoma significantly improves PFS.

TL;DR: For patients with stage B and C CLL first-line fludarabine and ChOP regimens both provided similar overall survival and close response rates, and better results than CAP, but there was an increase in clinical remission rate and a trend toward a better tolerance of fludARabine over ChOP that may influence the choice between these regimens as front-line treatments in patients with CLL.

TL;DR: With a 5-year follow-up, the combination of rituximab with CHVP+I provides superior disease control in follicular lymphoma patients despite a shorter duration of chemotherapy.

TL;DR: Evidence of a significantly reduced survival in patients with neurolisteriosis treated with adjunctive dexamethasone is found, and the time window for fetal losses is determined, which is higher than reported elsewhere.

TL;DR: Investigating whether the introduction of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation (ASCT) improves outcome found it should be considered standard of care in patients aged 65 years or younger with mantle cell lymphoma.